EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Clinicopathological and prognostic significance of HER2-low expression in advanced gastric cancer: a retrospective observational study

Yukiya Narita iD, Taro Mizuno iD, Yasunobu Ishizuka iD, Tomoki Sakakida iD, Toshiki Masuishi iD, Hiroya Taniguchi iD, Shigenori Kadowaki iD, Kazunori Honda iD, Masashi Ando iD, Masahiro Tajika iD, Daisuke Takahari iD, Kei Muro iD

The Oncologist · 04.07.2025 · 30 (7)

DOI: 10.1093/oncolo/oyae328 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift The Oncologist, online erschienen am 02.12.2024. Verfasst von Yukiya Narita und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya 484-8681, Japan. Hauptthemen laut MEDLINE: Stomach Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Biomarkers, Tumor. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Human epidermal growth factor receptor 2 (HER2) status is a critical biomarker in advanced gastric cancer (AGC). While the role of HER2-positive tumors in guiding targeted therapies is well-established, the clinical implications of HER2-low expression, defined as immunohistochemistry (IHC) 1+ or IHC 2+/in situ hybridization-negative (ISH-negative), remain undetermined. The aim of this study was to investigate the prognostic significance and clinicopathological features of HER2-low AGC. Patients and methods This retrospective analysis involved patients with AGC treated with first-line fluoropyrimidine and platinum-based chemotherapy from 2011 to 2020. Patients were categorized into HER2-zero (HER2 IHC 0), HER2-low (IHC 1+ or 2+/ISH-negative), and HER2-positive (IHC 2+/ISH-positive or 3+) groups.

Results

Among 548 patients analyzed, 33.0%, 45.1%, and 21.8% were classified as HER2-zero, HER2-low, and HER2-positive, respectively. The proportions of male patients, intestinal-type histology, esophagogastric junction/cardia involvement, metastatic disease status, ≥2 metastatic sites, liver metastasis, lymph node metastasis, and high serum carcinoembryonic antigen levels were gradually elevated in the HER2-zero, HER2-low, and HER2-positive groups. Overall survival (median) was 13.8, 13.6, and 23.0 months, respectively, with a non-significant trend favoring HER2-positive over HER2-low (adjusted hazard ratio: 0.80; P = .0672). A delayed separation of Kaplan-Meier curves for overall survival between the HER2-zero and HER2-low groups was observed, without reaching statistical significance (adjusted hazard ratio: 1.12; P = .2568).

Conclusion

Patients with HER2-low status exhibited intermediate and specific clinicopathological features within the HER2-negative category. In terms of prognosis, HER2-low patients showed a worsening trend compared with HER2-positive patients. This evidence implies that HER2-low status represents a distinct clinical subset, bridging the gap between the HER2-zero and HER2-positive profiles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsErb-b2 Receptor Tyrosine KinasesBiomarkers, TumorHumansMaleFemaleRetrospective StudiesPrognosisMiddle AgedAgedAdultAged, 80 and over

Stichwörter der Autor:innen

HER2-lowHER2-positivechemotherapygastric cancer

Substanzen

Erb-b2 Receptor Tyrosine KinasesBiomarkers, TumorERBB2 protein, human

Autor:innen und Institutionen

  • Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya 484-8681, Japan.
  • Department of Endoscopy, Aichi Cancer Center Hospital, Nagoya, 484-8681, Japan.
  • Department of Medical Oncology, Graduate School of Medicine, Gunma University, Maebashi 371-5811, Japan.

ORCID-Profile: Yukiya Narita, Taro Mizuno, Yasunobu Ishizuka, Tomoki Sakakida, Toshiki Masuishi, Hiroya Taniguchi, Shigenori Kadowaki, Kazunori Honda, Masashi Ando, Masahiro Tajika, Daisuke Takahari, Kei Muro

Zitieren

APA

Narita, Y., Mizuno, T., Ishizuka, Y., Sakakida, T., Masuishi, T., Taniguchi, H., Kadowaki, S., Honda, K., Ando, M., Tajika, M., Takahari, D., & Muro, K. (2025). Clinicopathological and prognostic significance of HER2-low expression in advanced gastric cancer: a retrospective observational study. The Oncologist, 30(7). https://doi.org/10.1093/oncolo/oyae328

Vancouver

Narita Y, Mizuno T, Ishizuka Y, Sakakida T, Masuishi T, Taniguchi H, et al. Clinicopathological and prognostic significance of HER2-low expression in advanced gastric cancer: a retrospective observational study. The Oncologist. 2025;30(7). doi:10.1093/oncolo/oyae328

BibTeX
@article{Narita2025,
  author = {Narita, Yukiya and Mizuno, Taro and Ishizuka, Yasunobu and Sakakida, Tomoki and Masuishi, Toshiki and Taniguchi, Hiroya and Kadowaki, Shigenori and Honda, Kazunori and Ando, Masashi and Tajika, Masahiro and Takahari, Daisuke and Muro, Kei},
  title = {Clinicopathological and prognostic significance of HER2-low expression in advanced gastric cancer: a retrospective observational study},
  journal = {The Oncologist},
  year = {2025},
  volume = {30},
  number = {7},
  doi = {10.1093/oncolo/oyae328}
}
Kostenlos starten →